COLLECTIVE QA REPORT: HYPERLIPIDEMIA

Review Period: Week	v Monthly	Quarterly Date of Review:
	<u> </u>	
Total # of patients seen:		Adverse Outcomes: Y N
 chosen at random and revie Hyperlipidemia indicators: 1. Documentation of p 2. Documentation of f 3. Were the following 4. If established dx of 	wed for quality monit personal history of hear amily and social histor included in every visit hyperlipidemia were l	(insert #) charts, identifiers listed below were toring. The charts were reviewed for the following rt disease: (HTN, CVA, A-Fib, MI etc) ry: (Smoking habits; family heart disease) t: Weight, B/P, diet and exercise education lipids ordered per office protocol Statin drug were LFTs ordered per office protocol
Date of Service		
D=Discussed –noted changes which are needed = Appropriate NA= Not applicable	1. 2. 3. 4. 5.	
Chart #/Identifier Date of Service		
Date of Service D=Discussed –noted	1.	
changes which are needed $\sqrt{=}$ Appropriate NA= Not applicable		
Chart #/Identifier		
		<u> </u>
Date of Service D =Discussed –notedchanges which are needed $$ = Appropriate NA =Not applicable	1. 2. 3. 4. 5.	
	1	
Chart #/Identifier		
Date of Service	1	
D = Discussed-noted changes which are needed $\sqrt{=}$ Appropriate NA = Not applicable	1. 2. 3. 4.	
	5.	

MD/DO has reviewed / discussed all of the above with CRNP. All adverse events have been reviewed and *noted with the letter A*.

_MD/DO Date: _____

___CRNP Date: _____